Psychosomatics 44:515-520, December 2003
© 2003 The Academy of Psychosomatic Medicine
Pharmacokinetic Drug Interactions of Morphine, Codeine, and Their Derivatives: Theory and Clinical Reality, Part II
Scott C. Armstrong, M.D., and
Kelly L. Cozza, M.D.
Dr. Armstrong is the Co-Medical Director, Center for Geriatric Psychiatry, Tuality Forest Grove Hospital, Forest Grove, Ore., and Associate Professor of Psychiatry, Oregon Health Sciences University, Portland, Ore. Dr. Cozza is the staff psychiatrist for the Infectious Disease Service, Department of Medicine, Walter Reed Army Medical Center, Washington, D.C., and Assistant Professor of Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, Md. Address correspondence to Dr. Armstrong, Tuality Forest Grove Hospital, 1809 Maple St., Forest Grove, OR 97116; scott.armstrong{at}tuality.org (e-mail).
The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.
ABSTRACT
Pharmacokinetic drug-drug interactions with codeine, dihydrocodeine, hydrocodone, oxycodone, and buprenorphine are reviewed in this column. These compounds have a very similar chemical structure to morphine. Unlike morphine, which is metabolized chiefly through conjugation reactions with uridine diphosphate glucuronosyl transferase (UGT) enzymes, these five drugs are metabolized both through oxidative reactions by the cytochrome P450 (CYP450) enzyme and conjugation by UGT enzymes. There is controversy as to whether codeine, dihydrocodeine, and hydrocodone are actually prodrugs requiring activation by the CYP450 2D6 enzyme or UGT enzymes. Oxycodone and buprenorphine, however, are clearly not prodrugs and are metabolized by the CYP450 2D6 and 3A4 enzymes, respectively. Knowledge of this metabolism assists in the understanding for the potential of drug-drug interactions with these drugs. This understanding is important so that clinicians can choose the proper dosages for analgesia and anticipate potential drug-drug interactions.
This article has been cited by other articles:
|
|
|
|
 
M. M Foisy, E. M Yakiwchuk, and C. A Hughes
Induction Effects of Ritonavir: Implications for Drug Interactions
Ann. Pharmacother.,
July 1, 2008;
42(7):
1048 - 1059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Goumon, A. Muller, E. Glattard, C. Marban, C. Gasnier, J.-M. Strub, S. Chasserot-Golaz, O. Rohr, G. B. Stefano, I. D. Welters, et al.
Identification of Morphine-6-glucuronide in Chromaffin Cell Secretory Granules
J. Biol. Chem.,
March 24, 2006;
281(12):
8082 - 8089.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chouinard, M. Tessier, G. Vernouillet, S. Gauthier, F. Labrie, O. Barbier, and A. Belanger
Inactivation of the Pure Antiestrogen Fulvestrant and Other Synthetic Estrogen Molecules by UDP-Glucuronosyltransferase 1A Enzymes Expressed in Breast Tissue
Mol. Pharmacol.,
March 1, 2006;
69(3):
908 - 920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. B. Sandson, S. C. Armstrong, and K. L. Cozza
An Overview of Psychotropic Drug-Drug Interactions
Psychosomatics,
October 1, 2005;
46(5):
464 - 494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. P. Yong, J. Ramirez, F. Innocenti, and M. J. Ratain
Effects of Ketoconazole on Glucuronidation by UDP-Glucuronosyltransferase Enzymes
Clin. Cancer Res.,
September 15, 2005;
11(18):
6699 - 6704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. H. Wynn, K. L. Cozza, M. J. Zapor, G. W. Wortmann, and S. C. Armstrong
Antiretrovirals, Part III: Antiretrovirals and Drugs of Abuse
Psychosomatics,
February 1, 2005;
46(1):
79 - 87.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2003
Academy of Psychosomatic Medicine.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
